Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)

NCT04887831 is registered in ClinicalTrials.gov with G1 Therapeutics, Inc. as lead sponsor.

NCT NCT04887831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04887831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
Lead sponsor
G1 Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 4, 2021
Completion date
March 1, 2024
Enrollment
92 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, chemotherapy-induced neutropenia, metastatic bladder cancer, myelosuppression adult, urothelial carcinoma